Тромболизис при инсульте.

[FRSM]

Practice
Uncertainties Page
Should more patients with acute ischaemic stroke receive thrombolytic treatment?
Joanna M Wardlaw, professor of applied neuroimaging 1, Peter A G Sandercock, professor of neurology1, Veronica Murray, senior scientist2

1 Division of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, 2 Division of Medicine, Danderyd Hospital, Karolinska Institutet, SE-182 88 Stockholm, Sweden

.......

Uncertainties about thrombolysis in acute ischaemic stroke

What is the size of the reduction in death or dependency when treatment is given at different times after stroke onset?

What is the latest time for worthwhile benefit, and could it be more than six hours?

[Ссылки доступны только зарегистрированным пользователям ]

[Ссылки доступны только зарегистрированным пользователям ]

What is the effect on death?

Is the current upper age limit for treatment of 80 years justified?

What key clinical and radiological features identify patients most (or least) likely to benefit?

Should antithrombotics (an antiplatelet or anticoagulant) be coadministered to reduce the risk of early reocclusion after initial successful reperfusion?